News for Agent

Daily business news: funding, M&A, launches

Product Launches

Creative Biolabs Highlights iPSC Neural Models and Microfluidic Culture for Neurological Research

By ·

Key takeaways

  • Creative Biolabs is highlighting iPSC-derived cortical, dopaminergic, motor and sensory neurons plus neural progenitors and glial populations.
  • The company's microfluidic offerings include gradient-generating platforms and membrane-separated culture devices for barrier and interface studies.
  • Creative Biolabs says disease-relevant phenotypes should be confirmed experimentally rather than inferred from a donor's diagnosis.

Creative Biolabs is highlighting induced pluripotent stem cell differentiation, disease-relevant neural models and microfluidic cell culture for neurological research and early drug evaluation, the Shirley, NY-based contract research organization said in a 24-7 Press Release dated November 17, 2026. The company said the offerings are meant to help research teams design experiments around specific disease mechanisms.

Creative Biolabs' iPSC Neuron and Disease Model Range

Creative Biolabs said its iPSC-derived neuronal differentiation services cover cortical, dopaminergic, motor and sensory neurons, with characterization options matched to the intended application. The neural model portfolio also includes neural progenitors, specialized neurons and glial populations, with patient-derived or genetically engineered disease models available.

For Parkinson's disease studies, the company points to iPSC-derived midbrain dopaminergic neurons for work on neuronal vulnerability, mitochondrial stress and candidate-compound responses. For ALS, it cites motor neurons as a system for examining neurite integrity and disease-associated cellular phenotypes. Creative Biolabs said researchers should define the primary endpoint before choosing a model, and that a compound-response study may need matched disease and control lines, including isogenic controls where appropriate, along with consistent viability and a quantitative readout such as neurite length or cell survival.

Microfluidic Devices for Gradient and Barrier Studies

The company's cell culture and organ-on-chip model development services include gradient-generating platforms that establish controlled concentration profiles and membrane-separated culture devices for studying cellular interfaces. Creative Biolabs said such designs may suit blood-brain barrier models investigating transport or interactions across a cellular barrier, provided the appropriate cell types and functional validation are included.

For chip-based experiments, the company said investigators should assess cell compatibility, flow conditions, assay reproducibility and relevant functional measures, and should consider compound loss to device materials when interpreting exposure-response relationships. In barrier studies, permeability and barrier integrity should be evaluated together to distinguish transport from nonspecific leakage, and in vitro transport results alone cannot establish in vivo brain exposure.

Earlier Creative Biolabs Service Rollouts

Creative Biolabs has introduced several research service lines in recent months. On October 29, 2026, FinancialContent Business Page reported that the company offers directed iPSC differentiation, THP-1 macrophage modeling and immune checkpoint assays for drug discovery. On November 11, 2026, 24-7 Press Release reported that Creative Biolabs highlights single-cell RNA sequencing, single-nucleus RNA sequencing and single-molecule FISH to address cellular heterogeneity. On November 13, 2026, 24-7 Press Release reported that the company offers AI-assisted antibody design and early developability assessment, including multispecific design, affinity maturation, and aggregation and viscosity prediction.

Researchers planning human neural disease studies can explore Creative Biolabs' stem cell therapy development services and discuss suitable cells, controls and experimental endpoints, the company said.

Companies in this story

Sources

Machine-readable: Markdown · JSON